Close

Express Scripts/AbbVie Deal a 'Double Whammy' for Gilead Sciences (GILD); Deal Could Have Sector Wide Repercussions

December 22, 2014 11:19 AM EST Send to a Friend
JPMorgan analyst Cory Kasimov weighed in on Gilead Sciences (NASDAQ: GILD), which is down 13.7% after Express Scripts (NASDAQ: ESRX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login